Spectrum Pharma: EVOMELA Receives FDA Approval For Two Indications - Quick Facts

(RTTNews) - Spectrum Pharmaceuticals (SPPI) announced the U.S. FDA has granted approval of EVOMELA for use in two indications: use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma; and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Spectrum Pharmaceuticals gained global development and commercialization rights to EVOMELA from Ligand Pharma (LGND) in March 2013. Ligand received a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.